Caricamento...

Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells

EGFR/HER2 are frequently expressed in MPM tissues, however, no studies have shown the clinical benefit of using EGFR/HER2-targeting drugs in patients with malignant pleural mesothelioma (MPM). It was reported that the tyrosine kinase inhibitor (TKI) lapatinib enhanced trastuzumab-mediated antibody-d...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncol Rep
Autori principali: OKITA, RIKI, SHIMIZU, KATSUHIKO, NOJIMA, YUJI, YUKAWA, TAKURO, MAEDA, AI, SAISHO, SHINSUKE, NAKATA, MASAO
Natura: Artigo
Lingua:Inglês
Pubblicazione: D.A. Spandidos 2015
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4722889/
https://ncbi.nlm.nih.gov/pubmed/26503698
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2015.4314
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !